In this retrospective pharmacovigilance analysis, we identified 49,223 females with breast cancer (aged 18–100 years), in which a CDK4/6 inhibitor (palbociclib, ribociclib, or abemaciclib) was recorded as the primary suspect drug. The gene discussed is CDK4; the disease is breast carcinoma.